Peripheral mononuclear cells and cytokine circulating levels during adalimumab therapy in patients with rheumatoid arthritis;Cellule mononucleate periferiche e livelli di citochine circolanti in corso di terapia con adalimumab in pazienti con artrite reumatoide

Recenti Progressi in Medicina

Volumn 96, Issue 9, 2005, Pages 424-427

  Benucci, Maurizio ^a,b   Li Gobbi, Francesca ^a   Fossi, Fiammetta ^a   Cammelli, Emanuela ^b   Manfredi, Mariangela ^b  

^a Dipartimento Medicina Interna   (Italy)

^b SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

Adalimumab; Cytokine; Peripheral mononuclear cells

Indexed keywords

ADALIMUMAB; CD14 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 6; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MONONUCLEAR CELL; RHEUMATOID ARTHRITIS; TIME SERIES ANALYSIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; METHOTREXATE; METHYLPREDNISOLONE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 25144520905     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Lipsky P, van der Heijde D, St Clair E, Furst D, Breedveld F, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis (ATTRACT study). N Eng J Med 2000; 343: 1594-602.
2. Weinblatt ME, Kremer JM, Bankhurst AD. A trial of etanercept, a reconbinant tumor necrosis factor receptor/Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Eng J Med 1999; 340: 253-9.
3. Weinblatt M, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbera CA, Teoh LA. Adalimumab a fully human anti-tumor necrosis factor α monoclonal antibody for treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
4. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
5. Day R. Adverse reactions to TNFα inibitors in rheumatoid arthritis. Lancet 2002; 359: 540-1.
6. Li Gobbi F, Benucci M, Del Rosso A. Pneumonitis caused by Legionella pneumoniae in a patient with rheumatoid arthritis treated with anti TNFα (infliximab). J Clin Rheumatol 2005; 11: 119-20.
7. Benucci M, Li Gobbi F, Fossi F, Manfredi M, Del Rosso A. Drug induced lupus after treatment with Infliximab in rheumatoid artrhritis. J Clin Rheumatol 2005; 11: 47-9.
8. Kavanaugh A, Greenwald M, Zizic T. Immune response is not affected by Adalimumab therapy. Ann Rheum Dis 2003; 62(S1): 169.
9. Lorenz HM, Grunke A, Hieronimus T. In vivo blokade of tumor necrosis factor-α patients with rheumatoid arthritis: long term effects after repeted infusion of chimeric monoclonal antibody cA2. J Rheumatol 2000; 27: 304-10.
10. Weisman MH. What are the risks of biologic therapy in rheumatoid artrhritis? An update of safety. J Rheumatol 2002; 65(suppl): 33-8.
11. Jewett A, Bonavida B. Target induced inactivation and cell death by apoptosis in a subset of human NK cells. J Immunol 1996; 156: 907.
12. Jewett A, Cavalcanti M, Bonavida B. Pivotal role of endogenous TNF-alpha in the induction of functional inactivation and apoptosis in NK cells. J Immunol 1997; 159: 4815.
13. Jewett A, Bonavida B. MHC-class I antigens regulate both the function and the survival of human peripheral blood NK cells: role of endogenously secreted TNF-alpha. Clinical Immunol 2000; 96: 19-28.
14. Taylor PC, Chapman P, Elliott MJ. Reduced granulocyte traffic and chemotactic gradients in rheumatoid joint following treatment with anti-TNF alpha monoclonal antibodies. Br J Rheumatol 1998; 37 suppl 1: 29.
15. Paleolog EM, Hunt M, Elliott MJ. Deactivation of vascular endothelium by monoclonal anti-TNF alpha antibody in rheumatoid arthritis. Arthritis Rheum 1996; 39: 1082-91.
16. Maurice MM, van der Graaff WL, Leow A. Treatment of rheumatoid arthritis with monoclonal anti tumor necrosis factor alpha antibody results in accumulation of TH1 CD4+ T cells in peripheral blood. Arthritis Rheum 1998; 41: S165.
17. Kaufmann SHE. How can immunology contribute to the control of tuberculosis? Nature Rev Immunol 2001; 1: 20-30.
18. Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, Tsang E. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tubercolosis: possible role for limiting pathology. Infect Immun 2001; 69: 1847-55.
19. Benucci M, Li Gobbi F, Del Rosso A, Manfredi M. Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult onset Still's disease. First case report. C1 Exp Rheumatol 2005: in corso di pubblicazione.
20. Verhoef CM, van Roon JA, Vianen ME, Bijlsma JW, Lafeber FP. Interleukin 10(IL-10), not IL-4 or interferon-gamma production, correlates with progression of joint destruction in rheumatoid arthritis. J Rheumatol 2001; 28: 1960-6.